



RNS Number : 4141J
Roquefort Therapeutics PLC
05 April 2024

5 April 2024

Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")

Response to Share Price Movement

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth oncology market, notes recent bulletin board speculation about a placing that the Company may be undertaking.

The Company recently engaged its advisers to commence a process of market soundings in relation to a potential fundraise. However, in response to incorrect bulletin board comments regarding a speculative placing price and resulting unusual share price movements, the Board has decided to not proceed with any potential placing at this time.

As previously announced, Roquefort Therapeutics remains focused on completing an out-licensing agreement during the course of 2024 with potential Big Pharma partners and will update the market when a binding agreement is entered into.

ENDS

Enquiries:

Roquefort Therapeutics plc

Stephen West (Chairman) / Ajan Reginald
(CEO)

+44 (0)20 3918
8633

Hybridan LLP (Joint Broker)

Claire Louise Noyce

+44 (0)203 764
2341

Optiva Securities Limited (Joint Broker)

Christian Dennis

+44 (0)20 3411
1881

Buchanan (Public Relations)

Ben Romney / Jamie Hooper / George Beale

+44 (0)20 7466
5000

LEI: 254900P4SISIWOR9RH34

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.

Roquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:

- Midkine antibodies with significant *in vivo* efficacy and toxicology studies;
- Midkine RNA therapeutics with novel anti-cancer gene editing action;
- Midkine mRNA therapeutics with novel anti-cancer approach;
- STAT-6 siRNA therapeutics targeting solid tumours with significant *in vivo* efficacy; and
- MK cell therapy with direct and NK cell-mediated anti-cancer action

For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on X (formerly Twitter).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

SPMQKQBDDBKBNQK

Anonymous (not verified)

Response to Share Price Movement

34201650

A

Fri, 04/05/2024 - 07:00

LSE RNS

Company Announcement - General

ROQ